Q3 FY2026 · ended Sep 26, 2026 · Revenue $142.44M, +2.7% YoY · Filed Nov 2, 2026
Bioventus Inc. (BVS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 26, 2026, it reported revenue of $142.4 million and net income of $6.0 million. Free cash flow was $20.3 million. As of Sep 26, 2026 it held $34.1 million in cash and investments and $244.2 million in total debt.
Revenue
$142.44M
+2.7% vs year-ago quarter
Net income
$5.99M
+89.8% vs year-ago quarter
Operating cash flow
$20.66M
-31.4% vs year-ago quarter
Free cash flow
$20.32M
-31.4% vs year-ago quarter
EPS
$0.08
+60.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
—
Net cash
$-210.02M
Q3 FY2026
Operating margin
9.7%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BVS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1665988
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 26, 2026 |
Q2 FY2026 Jun 27, 2026 |
Q1 FY2026 Mar 28, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 27, 2025 |
|---|---|---|---|---|---|
| Revenue | $142.4M | $153.2M | $132.1M | $157.9M | $138.7M |
| Operating income | $9.7M | $19.1M | $8.4M | $19.5M | $11.3M |
| Net income | $6.0M | $33.4M | $3.1M | $14.8M | $3.2M |
| Diluted EPS | $0.08 | $0.47 | $0.04 | $0.21 | $0.05 |
| Operating cash flow | $20.7M | $19.9M | $8.9M | $38.0M | $30.1M |
| Free cash flow | $20.3M | $18.9M | $8.4M | $37.4M | $29.6M |
| Total assets | $673.4M | $673.3M | $650.5M | $683.6M | $701.6M |
| Total liabilities | $381.6M | $395.9M | $416.3M | $455.1M | $494.3M |
| Stockholders' equity | $240.5M | $228.3M | $188.9M | $184.1M | $166.1M |
| Cash and investments | $34.1M | $33.0M | $37.9M | $53.5M | $44.4M |
| Total debt | $244.2M | $263.7M | $288.4M | $311.3M | $341.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 21, 2026 |
All 463 Bioventus Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.